SBP-9330

Investigated by: Camino Pharma, LLC · National Institute on Drug Abuse (NIDA) · Sanford Burnham Prebys · University of California, San Diego

today NCT04948827 · Ph 1

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT04948827	Jul 2021 → Mar 2023	—	Camino Pharma, LLC	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	SBP-9330	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04948827 ↗
Route	Oral	“SBP-9330 oral capsules” NCT04948827 ↗